Entrectinib (Rozlytrek™) was approved by the U.S. Food and Drug Administration in August 2019 as the third tumor-agnostic cancer drug, meaning it targets a specific mutation of the cancer, not the organ of origin. The other two currently approved tumor-agnostic drugs are larotrectinib and pembrolizumab.
Short summaries of newly approved oncology-related therapies or drugs with new indications.
View All Drug Education